Eli Lilly has announced new pricing measures across its Zepbound obesity medication line, including reductions for its two highest marketed doses. The company stated that the 12.5 mg and 15 mg strengths of Zepbound will be offered in single-dose vials for $499 per month via its LillyDirect self-pay platform.
Shipments of these discounted doses are scheduled to commence in early August. Medical professionals will be permitted to begin prescribing the new vials on July 7. According to Lilly, this move will make all approved Zepbound doses available at $499 or less per month for patients paying out-of-pocket, regardless of insurance coverage.
Lilly first introduced its single-dose vial program for self-pay customers the previous summer. The aim was to accommodate strong demand and enhance patient access to the treatment. The recent inclusion of the 12.5 mg and 15 mg vials completes the company’s effort to offer every dose of Zepbound through this pricing structure.
The broader context for this initiative includes limited insurance coverage for obesity medications. Despite the availability of FDA-approved options from both Eli Lilly and Novo Nordisk, many health plans do not provide extensive reimbursement for these drugs. In response, both companies have turned to direct-to-consumer models to increase availability and reduce costs for self-paying individuals.
Rhonda Pacheco, Vice President of Lilly’s U.S. cardiometabolic health unit, commented on the initiative in the press release, stating, “Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions.” She added that the new pricing offers another treatment alternative for patients and providers.
The announcement follows a similar pricing initiative from Novo Nordisk. In May, Novo introduced a one-time offer for its obesity drug Wegovy, giving self-paying customers access to a month’s supply at $199 through June 30. After that period, the cost will shift to $499 per month. The discount was directed at patients who had previously used compounded semaglutide before the U.S. Food and Drug Administration (FDA) prohibited the production and sale of such unauthorized copies on May 22.
Lilly and Novo Nordisk have both taken legal action against compounders who were manufacturing versions of GLP-1 medications during periods of shortage. These measures were part of a broader effort to maintain market share and control distribution channels for their approved products.
LillyDirect, the company’s direct-to-consumer online platform, was established last year to facilitate patient access to certain medications, including Zepbound. In February, the company expanded its available dosing options and reduced prices for users paying cash via this platform.
In a related development, CVS Health announced in May that it would remove Zepbound from some of its reimbursement lists starting July 1. However, it will continue coverage for Wegovy after securing a more favorable pricing agreement with Novo Nordisk.
Both Eli Lilly and Novo Nordisk are active competitors in the growing obesity treatment market, estimated at $150 billion. Recent prescription data shared by analysts suggests that Lilly has gained a market lead, surpassing Novo Nordisk, which had initially entered the market earlier.
In addition to direct website sales, both companies have been promoting access to their obesity medications through various telehealth services.
